Trial
NCT03895437
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Tolerion, Inc.
Collaborators
—
Condition
Diabetes Mellitus, Type 1
Intervention
TOL-3021
Why stopped
The DSMB concluded that there was a low probability the study would meet it is primary endpoint as designed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-20